Overview

Assessment of the Analgesic Effects of PF-06273340 in Healthy Volunteers Using Evoked Pain Endpoints

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This study will examine the activity of 2 different doses of PF-06273340 on a panel of evoked pain tests carried out from 0.5 to 10 hours following oral dosing in healthy male subjects
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Ibuprofen
Pregabalin